Profile

David D. Hurd, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

249 Ratings

David D. Hurd, M.D.

Professor,

Clinical Specialties

Acute and Chronic Leukemia, Hodgkin's Disease, Lymphomas, Multiple Myeloma, Non-Hodgkin's Lymphoma, Clinical Trials, Bone Marrow and Stem Cell Transplantation

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of Wisconsin-Madison , 1969
  • M.D., University of Illinois College of Medicine , 1974
  • Internship, Internal Medicine, University of Minnesota, 1975
  • Residency, Internal Medicine, University of Minnesota, 1977
  • Fellowship, University of Minnesota, 1979

Memberships

  • Am Assn Of Cancer Research
  • AAAS
  • Am Coll Of Physicians
  • Am Soc Of Clinical Oncology
  • Am Soc Of Hematology

NPI Number

  • 1962481879
David D. Hurd, M.D.

Doctor Rating

4.7 out of 5

249 Ratings

David D. Hurd, M.D.

Professor, Hematology & Oncology
Comprehensive Cancer Center

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm

Contact Information

Academic: 336-716-2088 | Department: 336-716-4464

Recent Publications

Wang W, Bergman S, Hurd D, Zamkoff K, Beaty M. Large granular lymphocytic leukemia after allogeneic hematopoietic stem cell transplant [abstract]. Lab Invest. 2014;94(Suppl 1):384A.

Duckworth K, Forti A, Russell G, Campbell C, Naik S, Hurd D, McQuellon R. Advance care planning information and distress in hematopoietic cell transplant candidates and proxies [abstract]. Psychooncology. 2013;22(Suppl 2):100-101.

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013;31(5):1311-1320.

Duckworth KE, Forti AM, Russell GB, Naik S, Hurd DD, McQuellon RP. Hematopoietic stem cell transplant candidate and designated proxy distress levels prior to hematopoietic stem cell transplantation. Am J Hosp Palliat Care. 2013;():.

Duckworth KE, Forti AM, Russell GB, Naik S, Hurd D, McQuellon RP. The process of advance care planning in HCT candidates and proxies: self-efficacy, locus of control, and anxiety levels. Am J Hosp Palliat Care. 2013;():.

Naik S, D'Agostino R Jr, Lamar Z, Graham RM, Vatca M, Agnew E, Higgins A, Levitan D, Hurd D. Outcomes of second transplants for disease recurrence or for myelodysplasia (MDS) developing after an initial transplant (Tx) [abstract]. Biol Blood Marrow Transplant. 2012;18(2 Suppl 2):S340-S341.

McQuellon R, Duckworth K, Campbell C, Russell G, Naik S, Levitan D, Zamkoff K, McQuellon BT, Hurd D. Fear of recurrence following hematopoetic stem cell transplantation [abstract]. Psychooncology. 2012;21(Suppl 1):127.

Wendtner C-M, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(3):417-423.

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A,. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.

Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758-765.

High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, Fenske TS, Cashen A, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Blood. 2012;120(21):Abstr 1623.

Loth K, Naik S, Kennedy LA, Levitan D, Zamkoff K, Hurd D. Infectious complications associated with the use of antithymocyte globulin in reduced intensity allogeneic transplants [abstract]. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S355-S356.

Naik S, Shope D, Albright C, Graham R, Levitan D, Zamkoff K, D'Agostino R Jr, Hurd D. Transplant outcomes in multiple myeloma patients younger versus older than 60 years of age in the era of newer targeted agents [abstract]. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S252-S253.

Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Hurd D, et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011;35(3):329-333.

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe L-A, Devine S, Farag S, Hurd D, Ball E, et al. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation:. Biol Blood Marrow Transplant. 2011;17(4):558-565.

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H, Peterson BA, Nadler LM, Freedman A, Hurd DD, et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011;52(4):587-596.

Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011;22(4):939-946.

Pomper GJ, Wilson E, Isom S, Hurd DD. A validation study of new cryopreservation bags for implementation in a blood and marrow transplant laboratory. Transfusion. 2011;51(6):1291-1295.

Campbell C, McQuellon R, Duckworth K, Russell G, Hurd D, Levitan D, Naik S, Zamkoff K, McQuellon B, Sommer J. Health related quality of life, depressive symptoms and distress before and after hematopoietic cell transplantation [abstract]. Psychooncology. 2011;20(Suppl 1):81.

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-5125.

Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S. Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Blood. 2011;118(21):1546.

Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Strader J, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): final results of a phase I study [abstract]. Blood. 2011;118(21):1705-1706.

Keung YK, Levitan D, Zamkoff K, Hurd D. Should the concern of myelodysplastic syndrome affect the decision of auto-SCT in lymphoma? [letter]. Bone Marrow Transplant. 2010;45(2):407-408.

Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Hurd DD, et al. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010;76(5):1305-1313.


McQuellon R, Campbell C, Russell G, Duckworth K, Sommer J, McQuellon B, Hurd D. Quality of survivorship, surveillance behavior and treatment satisfaction following hematopoietic cell transplantation [abstract]. Psychooncology. 2010;19(Suppl 1):S98-S99.

Ritter EM, Zamkoff KW, Levitan DA, Hurd DD. The importance of timing of hematopoietic stem cell transplantation (HSCT) in patients with T-cell lymphomas (T-NHL) [abstract]. Biol Blood Marrow Transplant. 2010;16(2 Suppl 2):S238.

McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104 [abstract]. J Clin Oncol. 2010;28(15 Suppl Pt 1):577s.

McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Levitan D, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma CALGB 100104 [abstract]. Blood. 2010;116(21):21-22.

Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Hurd DD, et al. Final results of the Phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 Study) [abstract]. Blood. 2010;116(21):591-592.

Voorhees PM, Gasparetto C, Osman K, Richards K, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Hurd DD, et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma [abstract]. Blood. 2010;116(21):815.

Danhauer SC, Vishnevsky T, Campbell CR, McCoy TP, Tooze JA, Kanipe KN, Arrington SA, Holland EK, Lynch MB, Hurd DD, Cruz J. Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of anxiety, perceived pain, and patient satisfaction. J Soc Integr Oncol. 2010;8(4):140-147.

Beaty MW, Pettenati M, Hurd DH [sic] [Hurd DD], Keung Y. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. Mod Pathol. 2009;22(Suppl 1):1161.

McClure White G, Campbell C, Russell G, Duckworth K, Hurd D, McQuellon R. Assessing distress and depression in hematopoietic stem cell transplant patients [abstract]. Psychooncology. 2009;18(Suppl 1):S43.

Wendtner CM, Mahadevan D, Coutre S, Hillmen P, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Furman R, Hurd D, et al. A phase I dose-escalation of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Haematologica. 2009;94(Suppl 2):371-372.

Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Lovato J, Torti SV, Torti FM, Molnar I, et al. The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol. 2009;2():article 44.

Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009;50(10):1589-1596.

Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, LaCasce AS, Blum KA, Byrd JC, Kelly M, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.

Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, et al. Recombinant interferon-alpha 2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009;50(10):1606-1617.

McCarthy PL, Owzar K, Stadtmauer EA, Giralt S, Hurd DD, Hassoun H, Hofmeister C, Richardson P, Weisdorf DJ, Pasquini MC, et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events [abstract]. Blood. 2009;114(22):1327.

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, DiPersio JF, et al. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Blood. 2009;114(22):1422.

Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J, Winans D, Moore DT, Hurd DD, et al. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase I study [abstract]. Blood. 2009;114(22):129-130.


Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol. 2008;26(14):2240-2243.

Keung Y, Beaty MW, Pettenati M, Levitan D, Molnar I, Thakuri M, Cruz J, Hurd DD. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. J Clin Oncol. 2008;26(Suppl):a18016.

Ferrans CE, Ryan C, Archer LE, Freels S, Lan L, Paskett E, Molokie R, Hurd DD, Kornblith AB. Factors contributing to cancer screening in African Americans [abstract]. J Clin Oncol. 2008;26(Suppl):a6514.

Giralt S, Mangan K, Maziarz R, Bubalo JS, Beveridge R, Hurd DD, Mendoza F, Rubenstein EB, DeGroot TJ, Schuster MW. Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT) [abstract]. J Clin Oncol. 2008;26(Suppl):a9617.

Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and Leukemia Group B study 10107. Leuk Lymphoma. 2008;49(7):1274-1278.


Powell B, D'Agostino R Jr, Levitan D, Ellis LR, Lyerly S, Skiles M, Manuel M, Harrelson R, Kimbrough C, Hurd DD. High dose cytarabine and clofarabine (HiDAC-->CLOF) in relapsed or refractory acute myeloid leukemia, a phase 2 trial [abstract]. Blood. 2008;112(11):676.

Fehniger TA, Larson S, Trinkaus K, Siegal MJ, DiPersio JF, Cashen AF, Hurd DD, Blum KA, Bartlett NL. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgin Lymphoma (cHL): preliminary results [abstract]. Blood. 2008;112(11):899-900.

Keung YK, Beaty MW, Pettenati M, Levitan D, Molnar I, Thakuri MC, Cruz J, Hurd DD. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. Blood. 2008;112(11):751.

Danhauer SC, Vishnevsky T, McCoy TP, Campbell CR, Tooze JA, Kanipe KN, Arrington SA, Lynch MB, Hurd DD, Cruz J, et al. Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of effects on anxiety, perceived pain, and patient satisfaction [abstract]. J Soc Integr Oncol. 2008;6(4):190.

Molnar I, Stark N, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Cambra S, McQuellon RP, Schwartz GG, et al. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)) [letter]. Leukemia. 2007;21(5):1089-1092.

Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007;2(5):445-449.

Huff JD, Keung Y-K, Thakuri M, Beaty MW, Hurd DD, Owen J, Molnar I. Copper deficiency causes reversible myelodysplasia. Am J Hematol. 2007;82(7):625-630.

Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies. Pharmacotherapy. 2007;27(10):1353-1360.

Copelan E, Casper JT, Carter SL, van Burik JH, Hurd D, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007;13(12):1469-1476.

Schuster MW, Mehta J, Waller EK, Rifkin RM, Micallef I, Hurd D, Parekh S, Hari P, Skikne BS, Shea TC, et al. A randomized placebo controlled phase II trial of prevention of severe oral mucositis using single dose velafermin in patients receiving myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT) [abstract]. Blood. 2007;110(11 Pt 1):190A.

Spielberger R, Territo M, Durrant S, Nimer S, McCarty J, Hurd D, Berger D, Aycock J, Chen M-G, Stiff P. No difference in survival or long-term disease outcomes in palifermin-treated patients with hematologic malignancies undergoing hematopoietic stem cell transplantation [abstract]. Blood. 2007;110(11 Pt 1):496A.

Storey JA, Connor R, Lewis ZT, Lovato J, Hurd D, Torti FM, Molnar I. The transfusion iron overload score is a potential predictor of survival in stem cell transplant patients [abstract]. Blood. 2007;110(11 Pt 1):336A.

Connor RF, Hurd D, Pettenati MJ, Koty P, Molnar I. Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia. Leuk Res. 2006;30(10):1249-1252.


Casale DA, Bartlett NL, Hurd DD, Foss F, Pro B, Sokol L, Lieberman R, Luz H. A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia [abstract]. Blood. 2006;108(11 Pt 1):771a.

Gupta P, Sanford BL, Yu D, Vij R, Hurd DD, Odenike O, Bloomfield CD, Hasserjian RP, Larson RA. A phase II study of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105 [abstract]. Blood. 2006;108(11 Pt 1):753a.

Damon LE, Johnson J, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Byrd JC, Kelly M, Linker C, Canellos GP. Immuno-chemotherapy (IC) and autologous stem cell transplantation (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909 [abstract]. Blood. 2006;108(11 Pt 1):774a.

Powell BL, Lovato J, Kimbrough C, Lyerly S, Galloway-Daniels S, Harrelson R, Keung YK, Thakuri MC, Molnar I, Levitan D, Hurd DD, et al. Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC-->CLOF) in relasped or refractory acute myeloid leukemia [abstract]. Blood. 2006;108(11 Pt 2):221b.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Specialties

Acute and Chronic Leukemia, Hodgkin's Disease, Lymphomas, Multiple Myeloma, Non-Hodgkin's Lymphoma, Clinical Trials, Bone Marrow and Stem Cell Transplantation
David D. Hurd, M.D.

David D. Hurd, M.D.

Professor, Hematology & Oncology
Comprehensive Cancer Center

Doctor Rating

4.7 out of 5

David D. Hurd, M.D.249 Ratings

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.7
Wait time at clinic
4

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.